AYTU BIOPHARMA INC
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
AYTU$1.81+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended | ||
|---|---|---|
| March 31, | ||
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(11,227) | $(14,594) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation, amortization and accretion | 6,328 | 6,699 |
| Stock-based compensation expense | 2,561 | 5,146 |
| Loss (gain) on derivative warrant liabilities | 5,467 | (6,167) |
| Amortization of senior debt discount | 463 | 413 |
| Inventory write-down | 476 | 199 |
| Impairment expense | — | 2,600 |
| Gain from contingent consideration | — | (504) |
| Other noncash adjustments | (50) | (29) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (988) | (12,335) |
| Inventories | (1,674) | (2,987) |
| Prepaid expenses and other current assets | 863 | (3,603) |
| Accounts payable | (2,937) | 3,720 |
| Accrued liabilities | (3,774) | 7,031 |
| Other operating assets and liabilities, net | 3,892 | (83) |
| Net cash used in operating activities | (600) | (14,494) |
| Cash flows from investing activities: | ||
| Other investing activities | (295) | 38 |
| Net cash (used in) provided by investing activities | (295) | 38 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of stock and warrants | 86 | 13,012 |
| Net proceeds received from, short-term line of credit | 18 | 6,590 |
| Payment made to fixed payment arrangement | (2,204) | (4,117) |
| Payment of stock issuance costs | (160) | (1,045) |
| Payments made to borrowings | (70) | (73) |
| Payment for debt issuance costs | — | (92) |
| Net cash (used in) provided by financing activities | (2,330) | 14,275 |
| Net change in cash and cash equivalents | (3,225) | (181) |
| Cash and cash equivalents at beginning of period | 22,985 | 19,360 |
| Cash and cash equivalents at end of period | $19,760 | $19,179 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $3,164 | $2,861 |
| Cash paid for income taxes | $562 | $— |
| Non-cash investing and financing activities: | ||
| Other noncash investing and financing activities | $718 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.